title: Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
abstract: When metastatic prostate cancer progresses despite androgen suppression but symptoms do not yet warrant cytotoxic therapy, abiraterone appears to prolong overall survival and to delay the onset of some cancer-related symptoms. But beware of cardiac and hepatic adverse effects that are inadequately documented.
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects*; D000736:Androstenes; D000737:Androstenols / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; C089740:abiraterone